UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/755,889	01/13/2004	Steven G. Nadler	D0284 NP	1732

23914 7590 02/01/2007

LOUIS J. WILLE
BRISTOL-MYERS SQUIBB COMPANY
PATENT DEPARTMENT
P O BOX 4000
PRINCETON, NJ 08543-4000

EXAMINER	
MONSHIPOURI, MARYAM	
ART UNIT	**PAPER NUMBER**
1656	

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	02/01/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No.	Applicant(s)	
	10/755,889	NADLER ET AL.	
	Examiner	Art Unit	
	Maryam Monshipouri	1656	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *1* MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☐ Responsive to communication(s) filed on _____.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *19* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *19* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date *filed 9/7/06*.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application
6) ☒ Other See attachment

Applicant's response to non-responsive notice filed 11/15/2006 is acknowledged. Applicant indicated that he/she provisionally elected to prosecute the invention drawn to a method of decreasing NFkB pathway activity through the inhibition of BCL-6 polypeptide expression (SEQ ID NO:18) even though the elected claim was drawn to a method of use of BCL6 polypeptide provided in SEQ ID NO:18. Therefore instant amended claim is drawn to the elected invention.

This argument was not entirely convincing because it is common knowledge that applicant, at the time of election, is fully aware of what the elected claim(s) is and what applicant incorporates in their remarks is a mere support of that election and at times a mere formality. However, as a matter of courtesy and in a gesture of cooperation, the examiner hereby enters applicant's amendment.

Claim 19 is pending and under examination.

Claim Rejections - 35 USC § 112

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 19 is rejected under 35 U.S.C. 102(b) as being anticipated by Taylor et al. (U.S. patent No. 6,140,125 issued 10/31/2000). Taylor in column 39 discloses a DNA sequence (namely SEQ ID NO:3, referred to as human bcl-6 gene) which encodes the human BCL-6 polypeptide of this invention and has 100% identity to SEQ ID NO:18 of this invention (see the attached sequence alignment). In column 18, Taylor claims a

method of inhibiting the expression of human bcl-6 in human cells comprising contacting said cells with antisense compounds so that the expression of human bcl-6 gene is inhibited. Since bcl-6 gene (or its expression products) and NFkB are members of the same pathway and NFkB is one of the downstream substrates of bcl gene (and/or its expression product) by inherency, inhibition of bcl-6 gene inherently decreases the activity of NFkB, anticipating this invention.

No claim is allowed.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maryam Monshipouri whose telephone number is (571) 272-0932. The examiner can normally be reached on 7:00 a.m to 5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleene Kerr Bragdon can be reached on (571) 272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

M.Monshi

Maryam Monshipouri Ph.D.

Primary Examiner

Attachment

4	3763	99.2	3720	2	US-08-553-541B-1	Sequence 1, Appli
5	3763	99.2	3720	3	US-09-268-202-1	Sequence 1, Appli
6	3763	99.2	3720	3	US-09-761-117-1	Sequence 1, Appli
7	3763	99.2	3720	6	PCT-US94-06669-1	Sequence 1, Appli
8	621.5	16.4	2769	3	US-09-620-312D-309	Sequence 309, App
9	614.5	16.2	2680	3	US-09-063-035-1	Sequence 1, Appli
10	540	14.2	2289	3	US-09-949-016-1780	Sequence 1780, Ap
11	508	13.4	2184	3	US-09-949-016-4402	Sequence 4402, Ap
12	503	13.3	3052	3	US-10-104-047-959	Sequence 959, App
13	500	13.2	2920	3	US-09-620-312D-1084	Sequence 1084, Ap
14	498.5	13.1	2948	3	US-09-774-528-145	Sequence 145, App
15	498.5	13.1	2948	3	US-10-120-988-145	Sequence 145, App
16	495	13.1	2320	3	US-09-016-434-1054	Sequence 1054, Ap
17	491	12.9	1892	2	US-08-933-750C-66	Sequence 66, Appl
18	491	12.9	1892	3	US-09-234-613-66	Sequence 66, Appl
19	489	12.9	2441	3	US-09-949-016-2756	Sequence 2756, Ap
20	483.5	12.7	3798	3	US-09-949-016-4204	Sequence 4204, Ap
21	482.5	12.7	3839	3	US-09-949-016-485	Sequence 485, App
22	482.5	12.7	156942	3	US-09-949-016-12227	Sequence 12227, A
23	482.5	12.7	156950	3	US-09-949-016-15946	Sequence 15946, A
24	482	12.7	19861	3	US-09-949-016-14498	Sequence 14498, A
25	480	12.7	2555	3	US-09-620-312D-1050	Sequence 1050, Ap
26	477	12.6	2804	3	US-09-949-016-2278	Sequence 2278, Ap
27	477	12.6	22294	3	US-09-949-016-14020	Sequence 14020, A
28	475.5	12.5	3252	3	US-09-774-528-104	Sequence 104, App
29	475.5	12.5	3252	3	US-10-120-988-104	Sequence 104, App
30	474.5	12.5	2784	3	US-10-104-047-1944	Sequence 1944, Ap
31	473	12.5	3090	3	US-10-104-047-191	Sequence 191, App
32	470.5	12.4	2771	3	US-09-976-594-691	Sequence 691, App
33	469.5	12.4	2925	3	US-09-620-312D-163	Sequence 163, App
34	468.5	12.4	2110	3	US-10-104-047-1778	Sequence 1778, Ap
35	465.5	12.3	3026	3	US-10-104-047-967	Sequence 967, App
36	465	12.3	3078	3	US-10-104-047-622	Sequence 622, App
37	465	12.3	3240	3	US-09-949-016-5548	Sequence 5548, Ap
38	464.5	12.2	2637	3	US-09-949-016-5623	Sequence 5623, Ap
39	464.5	12.2	27227	3	US-09-949-016-17365	Sequence 17365, A
40	464	12.2	2724	3	US-10-104-047-1127	Sequence 1127, Ap
41	463.5	12.2	2241	3	US-10-104-047-693	Sequence 693, App
42	462.5	12.2	2467	3	US-10-104-047-470	Sequence 470, App
43	462.5	12.2	2634	3	US-10-104-047-816	Sequence 816, App
44	461.5	12.2	1833	3	US-10-104-047-1491	Sequence 1491, Ap
45	461	12.2	2351	3	US-09-016-434-1337	Sequence 1337, Ap

ALIGNMENTS

RESULT 1
US-09-418-640-3
; Sequence 3, Application US/09418640
; Patent No. 6140125
; GENERAL INFORMATION:
; APPLICANT: Jennifer K. Taylor
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF BCL-6 EXPRESSION
; FILE REFERENCE: RTS-0102
; CURRENT APPLICATION NUMBER: US/09/418,640
; CURRENT FILING DATE: 1999-10-15
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 3
; LENGTH: 3536
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (328)..(2448)
US-09-418-640-3

Alignment Scores:

Pred. No.:	2.45e-279	Length:	3536
Score:	3793.00	Matches:	706
Percent Similarity:	100.0%	Conservative:	0
Best Local Similarity:	100.0%	Mismatches:	0
Query Match:	100.0%	Indels:	0
DB:	3	Gaps:	0

US-10-755-889-18 (1-706) x US-09-418-640-3 (1-3536)

```
Qy          1 MetAlaSerProAlaAspSerCysIleGlnPheThrArgHisAlaSerAspValLeuLeu 20
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        328 ATGGCCTCGCCGGCTGACAGCTGTATCCAGTTCACCCGCCATGCCAGTGATGTTCTTCTC 387

Qy         21 AsnLeuAsnArgLeuArgSerArgAspIleLeuThrAspValValIleValValSerArg 40
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        388 AACCTTAATCGTCTCCGGAGTCGAGACATCTTGACTGATGTTGTCATTGTTGTGAGCCGT 447

Qy         41 GluGlnPheArgAlaHisLysThrValLeuMetAlaCysSerGlyLeuPheTyrSerIle 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        448 GAGCAGTTTAGAGCCCATAAAACGGTCCTCATGGCCTGCAGTGGCCTGTTCTATAGCATC 507

Qy         61 PheThrAspGlnLeuLysCysAsnLeuSerValIleAsnLeuAspProGluIleAsnPro 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        508 TTTACAGACCAGTTGAAATGCAACCTTAGTGTGATCAATCTAGATCCTGAGATCAACCCT 567

Qy         81 GluGlyPheCysIleLeuLeuAspPheMetTyrThrSerArgLeuAsnLeuArgGluGly 100
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        568 GAGGGATTCTGCATCCTCCTGGACTTCATGTACACATCTCGGCTCAATTTGCGGGAGGGC 627

Qy        101 AsnIleMetAlaValMetAlaThrAlaMetTyrLeuGlnMetGluHisValValAspThr 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        628 AACATCATGGCTGTGATGGCCACGGCTATGTACCTGCAGATGGAGCATGTTGTGGACACT 687

Qy        121 CysArgLysPheIleLysAlaSerGluAlaGluMetValSerAlaIleLysProProArg 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        688 TGCCGGAAGTTTATTAAGGCCAGTGAAGCAGAGATGGTTTCTGCCATCAAGCCTCCTCGT 747

Qy        141 GluGluPheLeuAsnSerArgMetLeuMetProGlnAspIleMetAlaTyrArgGlyArg 160
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        748 GAAGAGTTCCTCAACAGCCGGATGCTGATGCCCCAAGACATCATGGCCTATCGGGGTCGT 807

Qy        161 GluValValGluAsnAsnLeuProLeuArgSerAlaProGlyCysGluSerArgAlaPhe 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        808 GAGGTGGTGGAGAACAACCTGCCACTGAGGAGCGCCCCTGGGTGTGAGAGCAGAGCCTTT 867

Qy        181 AlaProSerLeuTyrSerGlyLeuSerThrProProAlaSerTyrSerMetTyrSerHis 200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        868 GCCCCCAGCCTGTACAGTGGCCTGTCCACACCGCCAGCCTCTTATTCCATGTACAGCCAC 927

Qy        201 LeuProValSerSerLeuLeuPheSerAspGluGluPheArgAspValArgMetProVal 220
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        928 CTCCCTGTCAGCAGCCTCCTCTTCTCCGATGAGGAGTTTCGGGATGTCCGGATGCCTGTG 987

Qy        221 AlaAsnProPheProLysGluArgAlaLeuProCysAspSerAlaArgProValProGly 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        988 GCCAACCCCTTCCCCAAGGAGCGGGCACTCCCATGTGATAGTGCCAGGCCAGTCCCTGGT 1047

Qy        241 GluTyrSerArgProThrLeuGluValSerProAsnValCysHisSerAsnIleTyrSer 260
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1048 GAGTACAGCCGGCCGACTTTGGAGGTGTCCCCCAATGTGTGCCACAGCAATATCTATTCA 1107

Qy        261 ProLysGluThrIleProGluGluAlaArgSerAspMetHisTyrSerValAlaGluGly 280
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1108 CCCAAGGAAACAATCCCAGAAGAGGCACGAAGTGATATGCACTACAGTGTGGCTGAGGGC 1167

Qy        281 LeuLysProAlaAlaProSerAlaArgAsnAlaProTyrPheProCysAspLysAlaSer 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1168 CTCAAACCTGCTGCCCCCTCAGCCCGAAATGCCCCCTACTTCCCTTGTGACAAGGCCAGC 1227

Qy        301 LysGluGluGluArgProSerSerGluAspGluIleAlaLeuHisPheGluProProAsn 320
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1228 AAAGAAGAAGAGAGACCCTCCTCGGAAGATGAGATTGCCCTGCATTTCGAGCCCCCCAAT 1287

Qy        321 AlaProLeuAsnArgLysGlyLeuValSerProGlnSerProGlnLysSerAspCysGln 340
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1288 GCACCCCTGAACCGGAAGGGTCTGGTTAGTCCACAGAGCCCCCAGAAATCTGACTGCCAG 1347

Qy        341 ProAsnSerProThrGluAlaCysSerSerLysAsnAlaCysIleLeuGlnAlaSerGly 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1348 CCCAACTCGCCCACAGAGGCCTGCAGCAGTAAGAATGCCTGCATCCTCCAGGCTTCTGGC 1407

Qy        361 SerProProAlaLysSerProThrAspProLysAlaCysAsnTrpLysLysTyrLysPhe 380
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1408 TCCCCTCCAGCCAAGAGCCCCACTGACCCCAAAGCCTGCAACTGGAAGAAATACAAGTTC 1467

Qy        381 IleValLeuAsnSerLeuAsnGlnAsnAlaLysProGlyGlyProGluGlnAlaGluLeu 400
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1468 ATCGTGCTCAACAGCCTCAACCAGAATGCCAAACCAGGGGGGCCTGAGCAGGCTGAGCTG 1527

Qy        401 GlyArgLeuSerProArgAlaTyrThrAlaProProAlaCysGlnProProMetGluPro 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1528 GGCCGCCTTTCCCCACGAGCCTACACGGCCCCACCTGCCTGCCAGCCACCCATGGAGCCT 1587

Qy        421 GluAsnLeuAspLeuGlnSerProThrLysLeuSerAlaSerGlyGluAspSerThrIle 440
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1588 GAGAACCTTGACCTCCAGTCCCCAACCAAGCTGAGTGCCAGCGGGGAGGACTCCACCATC 1647

Qy        441 ProGlnAlaSerArgLeuAsnAsnIleValAsnArgSerMetThrGlySerProArgSer 460
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1648 CCACAAGCCAGCCGGCTCAATAACATCGTTAACAGGTCCATGACGGGCTCTCCCCGCAGC 1707

Qy        461 SerSerGluSerHisSerProLeuTyrMetHisProProLysCysThrSerCysGlySer 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1708 AGCAGCGAGAGCCACTCACCACTCTACATGCACCCCCCGAAGTGCACGTCCTGCGGCTCT 1767

Qy        481 GlnSerProGlnHisAlaGluMetCysLeuHisThrAlaGlyProThrPheAlaGluGlu 500
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1768 CAGTCCCCACAGCATGCAGAGATGTGCCTCCACACCGCTGGCCCCACGTTCGCTGAGGAG 1827

Qy        501 MetGlyGluThrGlnSerGluTyrSerAspSerSerCysGluAsnGlyAlaPhePheCys 520
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1828 ATGGGAGAGACCCAGTCTGAGTACTCAGATTCTAGCTGTGAGAACGGGGCCTTCTTCTGC 1887

Qy        521 AsnGluCysAspCysArgPheSerGluGluAlaSerLeuLysArgHisThrLeuGlnThr 540
```

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1888 AATGAGTGTGACTGCCGCTTCTCTGAGGAGGCCTCACTCAAGAGGCACACGCTGCAGACC 1947

Qy        541 HisSerAspLysProTyrLysCysAspArgCysGlnAlaSerPheArgTyrLysGlyAsn 560
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1948 CACAGTGACAAACCCTACAAGTGTGACCGCTGCCAGGCCTCCTTCCGCTACAAGGGCAAC 2007

Qy        561 LeuAlaSerHisLysThrValHisThrGlyGluLysProTyrArgCysAsnIleCysGly 580
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2008 CTCGCCAGCCACAAGACCGTCCATACCGGTGAGAAACCCTATCGTTGCAACATCTGTGGG 2067

Qy        581 AlaGlnPheAsnArgProAlaAsnLeuLysThrHisThrArgIleHisSerGlyGluLys 600
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2068 GCCCAGTTCAACCGGCCAGCCAACCTGAAAACCCACACTCGAATTCACTCTGGAGAGAAG 2127

Qy        601 ProTyrLysCysGluThrCysGlyAlaArgPheValGlnValAlaHisLeuArgAlaHis 620
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2128 CCCTACAAATGCGAAACCTGCGGAGCCAGATTTGTACAGGTGGCCCACCTCCGTGCCCAT 2187

Qy        621 ValLeuIleHisThrGlyGluLysProTyrProCysGluIleCysGlyThrArgPheArg 640
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2188 GTGCTTATCCACACTGGTGAGAAGCCCTATCCCTGTGAAATCTGTGGCACCCGTTTCCGG 2247

Qy        641 HisLeuGlnThrLeuLysSerHisLeuArgIleHisThrGlyGluLysProTyrHisCys 660
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2248 CACCTTCAGACTCTGAAGAGCCACCTGCGAATCCACACAGGAGAGAAACCTTACCATTGT 2307

Qy        661 GluLysCysAsnLeuHisPheArgHisLysSerGlnLeuArgLeuHisLeuArgGlnLys 680
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2308 GAGAAGTGTAACCTGCATTTCCGTCACAAAAGCCAGCTGCGACTTCACTTGCGCCAGAAG 2367

Qy        681 HisGlyAlaIleThrAsnThrLysValGlnTyrArgValSerAlaThrAspLeuProPro 700
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       2368 CATGGCGCCATCACCAACACCAAGGTGCAATACCGCGTGTCAGCCACTGACCTGCCTCCG 2427

Qy        701 GluLeuProLysAlaCys 706
                ||||||||||||||||||
Db       2428 GAGCTCCCCAAAGCCTGC 2445
```

```
RESULT 2
US-09-814-915A-90
; Sequence 90, Application US/09814915A
; Patent No. 6750015
; GENERAL INFORMATION:
;  APPLICANT: Horwitz, Kathryn
;  APPLICANT:  Richer, Jennifer
;  TITLE OF INVENTION: Progesterone Receptor-Regulated Gene Expression and Methods Related
;  TITLE OF INVENTION:  Thereto
;  FILE REFERENCE: 2848-39
;  CURRENT APPLICATION NUMBER: US/09/814,915A
;  CURRENT FILING DATE:  2002-03-21
;  PRIOR APPLICATION NUMBER: 60/214,870
;  PRIOR FILING DATE: 2000-06-28
;  NUMBER OF SEQ ID NOS: 108
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 90
;   LENGTH: 3536
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-814-915A-90

Alignment Scores:
Pred. No.:              2.45e-279       Length:         3536
Score:                  3793.00         Matches:        706
Percent Similarity:     100.0%          Conservative:   0
Best Local Similarity:  100.0%          Mismatches:     0
Query Match:            100.0%          Indels:         0
DB:                     3               Gaps:           0

US-10-755-889-18 (1-706) x US-09-814-915A-90 (1-3536)

Qy          1 MetAlaSerProAlaAspSerCysIleGlnPheThrArgHisAlaSerAspValLeuLeu 20
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        328 ATGGCCTCGCCGGCTGACAGCTGTATCCAGTTCACCCGCCATGCCAGTGATGTTCTTCTC 387

Qy         21 AsnLeuAsnArgLeuArgSerArgAspIleLeuThrAspValValIleValValSerArg 40
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        388 AACCTTAATCGTCTCCGGAGTCGAGACATCTTGACTGATGTTGTCATTGTTGTGAGCCGT 447

Qy         41 GluGlnPheArgAlaHisLysThrValLeuMetAlaCysSerGlyLeuPheTyrSerIle 60
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        448 GAGCAGTTTAGAGCCCATAAAACGGTCCTCATGGCCTGCAGTGGCCTGTTCTATAGCATC 507

Qy         61 PheThrAspGlnLeuLysCysAsnLeuSerValIleAsnLeuAspProGluIleAsnPro 80
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        508 TTTACAGACCAGTTGAAATGCAACCTTAGTGTGATCAATCTAGATCCTGAGATCAACCCT 567

Qy         81 GluGlyPheCysIleLeuLeuAspPheMetTyrThrSerArgLeuAsnLeuArgGluGly 100
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        568 GAGGGATTCTGCATCCTCCTGGACTTCATGTACACATCTCGGCTCAATTTGCGGGAGGGC 627
```